# Trump Plans To Sign Executive Order On The Psychedelic Ibogaine As Soon As This Week … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ibogaine-opioid-use-disorder-treatment-executive-order/ > **Published:** 2026-04-16T21:05:39-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:20:15-04:00 > **Clinical Summary:** Explore ibogaine opioid use disorder treatment and Trump's executive order advancing psychedelic medicine access with clinical safety focus. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Psychedelics[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)Opioid Use DisorderPolicyCardiac Safety Why This Matters Ibogaine represents a unique psychedelic with distinct pharmacological mechanisms that could address opioid use disorder through different pathways than existing treatments. Any federal policy shift toward psychedelic medicine access requires clinical understanding of both therapeutic potential and significant safety considerations. Clinical Summary Ibogaine is a naturally occurring psychoactive compound from the Tabernanthe iboga plant, studied primarily for opioid use disorder treatment. Unlike other psychedelics, ibogaine acts on multiple neurotransmitter systems including opioid, serotonin, and dopamine receptors, potentially interrupting addiction pathways. The compound carries notable cardiac risks, including QT prolongation and potential fatal arrhythmias, requiring careful medical supervision. Current research is limited but suggests potential for reducing opioid withdrawal symptoms and craving, though optimal protocols and patient selection criteria remain undefined. Dr. Caplan’s Take “Ibogaine’s cardiac toxicity profile means this isn’t a compound for casual policy experimentation — any expanded access framework must prioritize rigorous medical oversight and patient screening. We need clear protocols before we need broader access.” Clinical Perspective 🧠 Clinicians should understand that ibogaine differs significantly from psilocybin or MDMA in both mechanism and risk profile. Any policy development should emphasize medical supervision, cardiac monitoring capabilities, and defined patient selection criteria. Practitioners should await clear clinical guidelines rather than attempting to incorporate ibogaine based on policy changes alone. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trump%20Plans%20To%20Sign%20Executive%20Order%20On%20The%20Psychedelic%20Ibogaine%20As%20Soon%20As%20This%20...%20%40drcaplan&url=https%3A//www.marijuanamoment.net/trump-plans-to-sign-executive-order-on-the-psychedelic-ibogaine-as-soon-as-this-week-report-says/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.marijuanamoment.net/trump-plans-to-sign-executive-order-on-the-psychedelic-ibogaine-as-soon-as-this-week-report-says/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trump%20Plans%20To%20Sign%20Executive%20Order%20On%20The%20Psychedelic%20Ibogaine%20As%20Soon%20As%20This%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.marijuanamoment.net/trump-plans-to-sign-executive-order-on-the-psychedelic-ibogaine-as-soon-as-this-week-report-says/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.marijuanamoment.net/trump-plans-to-sign-executive-order-on-the-psychedelic-ibogaine-as-soon-as-this-week-report-says/](https://www.marijuanamoment.net/trump-plans-to-sign-executive-order-on-the-psychedelic-ibogaine-as-soon-as-this-week-report-says/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What medical areas does this cannabis research relate to?](#What_medical_areas_does_this_cannabis_research_relate_to) - [How does this relate to opioid addiction treatment?](#How_does_this_relate_to_opioid_addiction_treatment) - [What type of policy developments are discussed?](#What_type_of_policy_developments_are_discussed) - [Why should healthcare providers pay attention to this news?](#Why_should_healthcare_providers_pay_attention_to_this_news) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that [healthcare professionals](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) should monitor closely. #### What medical areas does this cannabis research relate to? The article focuses on psychedelics, [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/), and opioid use disorder treatment. It also addresses policy implications in these therapeutic areas. #### How does this relate to opioid addiction treatment? The research appears to examine how cannabis or psychedelic therapies might be integrated into opioid use disorder treatment protocols. This represents an emerging area of clinical interest for addiction medicine specialists. #### What type of policy developments are discussed? The article covers policy changes related to psychedelic and [cannabis therapies](https://cedclinic.com/deep-reading-decline-digital-age-insights/) in addiction medicine. These developments may impact how clinicians can legally prescribe or recommend these treatments for opioid use disorder. #### Why should healthcare providers pay attention to this news? As an emerging finding with notable clinical interest, this research could influence future treatment guidelines for addiction medicine. Healthcare providers should stay informed about these developments as they may affect [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) options and treatment protocols. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental …](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) Learn about Trump's executive order speeding up legal access to psychedelics for mental health patients, highlighting policy shifts. [Read More](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) [Podcasters, Presidents, and Psychedelics: How Joe Rogan Got Trump Into Ibogaine](https://cedclinic.com/ibogaine-addiction-treatment-psychedelic-research-update/) Explore the influence of media and public figures on psychedelic policy, focusing on Joe Rogan's role in promoting ibogaine. [Discover More](https://cedclinic.com/ibogaine-addiction-treatment-psychedelic-research-update/) [A Review of Trump’s Recent Psychedelic Executive Order – Drug Science](https://cedclinic.com/psychedelic-executive-order-analysis-clinical-impact/) An analytical review of Trump's executive order on psychedelics, discussing implications for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and policy. [Learn More](https://cedclinic.com/psychedelic-executive-order-analysis-clinical-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).